Solventum (SOLV) is coming into focus as investors watch for its upcoming fiscal fourth quarter 2025 earnings, following raised full year EPS guidance and management’s continued emphasis on organic growth and cost initiatives.

Despite a softer 1 day and 1 month share price return, Solventum’s 90 day share price return of 9.63% and 1 year total shareholder return of 5.23% suggest momentum has picked up recently as investors weigh the raised EPS guidance and upcoming earnings against its current US$78.91 share price.

If Solventum’s update has you thinking about where capital might work hardest in healthcare, it could be a good moment to scan opportunities across healthcare stocks.

With Solventum trading at US$78.91, alongside an indicated intrinsic discount of about 41% and a roughly 12% gap to the analyst price target, you have to ask: is this a genuine value gap, or is future growth already priced in?

Most Popular Narrative: 10.9% Undervalued

Against Solventum’s last close at $78.91, the most followed narrative anchors on a fair value of about $88.55. This frames a modest valuation gap built on detailed long term earnings and cash flow assumptions.

Execution of multi-year operational streamlining and ERP implementations post-spin-off from 3M is progressing ahead of plan, with full completion expected by 2027; as separation-related costs drop off, this should enhance free cash flow, operating margin, and ultimately net earnings.

Curious what sits underneath that fair value claim? The narrative leans on changing profit margins, cash generation and a different future earnings multiple than today. The full set of assumptions is where the story really gets interesting.

Result: Fair Value of $88.55 (UNDERVALUED)

However, the thesis still hinges on the smooth execution of the 3M separation and ERP rollout, as well as demand holding up as SKU rationalization and order timing effects unwind.

Build Your Own Solventum Narrative

If you see the numbers differently, or prefer to test your own assumptions against the data, you can build a custom thesis in a few minutes by starting with Do it your way.

A great starting point for your Solventum research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Solventum is on your radar, do not stop there. Widening your watchlist now can help you spot opportunities before they become crowded trades.

• Scan for potential mispriced names by checking these 871 undervalued stocks based on cash flows that might fit the kind of risk and reward profile you are hunting for.
• Target fast moving themes in artificial intelligence with these 23 AI penny stocks and see which companies line up with your view of where the technology is heading.
• Position your portfolio for income potential by reviewing these 13 dividend stocks with yields > 3%, focusing on businesses offering yields above 3% that align with your return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.